| October 10, 2013 | ISSUE NUMBER 321 VOL 11 |
Healthcare Reform
National Chains Carefully Circle Obamacare
While US pharma anxiously watches the initial roll out of Obamacare, there are those entities closely associated with the innovator Rx business that have a very different view on what Obamacare means to their concerns. Who are these pharmaceutical colleagues? They are the national chain drug stores like CVS, Rite Aid, Walgreens, etc. And what makes them so enthusiastic about Obamacare? Many things, actually, writes Tom Norton ...Read more
Video
Pfizer on the Impact of Transparency
George Mina, Pfizer's Director/TL-Data Strategy & Reconciliation-Transparency Medical Division, talks to PharmExec TV about the challenges of implementing the Physician Payment Sunshine Act for pharmaceutical companies ...View here
Biopharma
Tweaking the Imperfections: A Lesson from Biotech
An increasing number of small biotech companies are being hatched to focus on a single disease or condition. One such company, Dart Therapeutics has taken on Duchenne Muscular Dystrophy (DMD). Dart’s strategy focuses on tweaking the imperfections of promising therapies and changing the risk equation in clinical trials to gain efficiency in time and investment. And true to its formation, patient groups are integral in the decision-making process
...Read more
Biopharma
Training: A Crucial Activity for Any Biotech
Codifying the elements of a training program will help a company maintain compliance and address regulatory concerns about employee qualifications that might arise during inspections, writes Susan J. Schniepp. And there should be four parts to any training program ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now.
New eBook
Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Pharmaceutical brand marketers are facing a paradigm shift in the way they market patient access solutions. As they navigate through the dynamics of a regionalized market, shrinking budgets and the challenges of tactical implementation, they require a consultative relationship with vendor providers. The question then is: Can the pharmaceutical marketer rely on one vendor to deliver customized, innovative solutions over the life of their brand?
...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now.
|
|
|
|
 //Daiichi Sankyo announced changes to its senior leadership team in the US. John Gargiulo will step down as President and CEO of Daiichi Sankyo Inc. His replacement is Dr Glenn Gormley, who becomes President and Chairman and will also continue as President of Pharma Development, Global Head of R&D and Senior Executive Officer. Gargiulo will also leave his role as Head of Daiichi's commercial division, to be replaced by Greg Barrett, currently Acting President, Daiichi Sankyo Administrative and Commercial Operations.//Acord Therapeutics Inc. (Ardsley, NY) appointed Michael Rodgers as Chief Financial Officer. The previous CFO, David Lawrence, moved to the position of Chief Business Officer.//KV Pharmaceutical (Chesterfield, MO) named Joseph Mahady, formerly President of Wyeth, as its new Chairman.// |
|
|
|
|
|
 |
|
|
| |
|
|
 |
|
 |
Should government funding for the US National Institutes of Health be exempted from federal budget sequestration cuts, debt ceiling negotiations and future government shutdowns?
|
|
|
|
